Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor

We evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD5718, a novel 5‐lipooxygenase activating protein (FLAP) inhibitor, in a randomized, single‐blind, placebo‐controlled, first‐in‐human (FIH) study consisting of single and multiple ascending dosing (SAD and MAD) for 10 day...

Descripción completa

Detalles Bibliográficos
Autores principales: Ericsson, Hans, Nelander, Karin, Lagerstrom‐Fermer, Maria, Balendran, Clare, Bhat, Maria, Chialda, Ligia, Gan, Li‐Ming, Heijer, Maria, Kjaer, Magnus, Lambert, John, Lindstedt, Eva‐Lotte, Forsberg, Gun‐Britt, Whatling, Carl, Skrtic, Stanko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944575/
https://www.ncbi.nlm.nih.gov/pubmed/29517132
http://dx.doi.org/10.1111/cts.12546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944575/
https://www.ncbi.nlm.nih.gov/pubmed/29517132
http://dx.doi.org/10.1111/cts.12546

Ejemplares similares